Skip to main content

Advertisement

SpringerLink
Log in

Management of Locally Advanced and Metastatic Esophageal Cancer in the Older Population

  • Geriatric Oncology (AR MacKenzie, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review aims to synthesise the current literature on the management of early-stage and metastatic esophageal cancers, focusing on the older population. In particular, we aim to dissect out the elderly-specific data from the relevant trials and to discuss the issues unique to this population.

Recent Findings

While surgery is the curative modality in esophageal malignancies, the CROSS, MAGIC and FLOT trials demonstrate a clear advantage to neoadjuvant therapy (chemotherapy and chemoradiotherapy). These trials, however, included few elderly patients. There is a similar lack of elderly-specific data in the metastatic setting.

Summary

Esophageal malignancies remain highly lethal with increasing incidence with age. Despite the relative lack of elderly-specific data, the fit older population appear to similarly benefit from multimodal therapy in early-stage and palliative therapy in metastatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. SEER Cancer Statistics Review, 1975-2015 [Internet]. Surveillance Research Program of the NCI. 2018. Available from: https://seer.cancer.gov/csr/1975_2015/.

  2. • van Putten M, de Vos-Geelen J, Nieuwenhuijzen GAP, Siersema PD, Lemmens V, Rosman C, et al. Long-term survival improvement in oesophageal cancer in the Netherlands. Eur J Cancer. 2018;94:138–47 This article reports the trends in diagnosis, treatment, histology and survival for oesophageal cancer in the Netherlands Cancer Registry in the period 1989–2014. It reports incidence, subtype, survival, age and treatment modality—thus yielding extensive demographic and therapeutic data across time.

    PubMed  Google Scholar 

  3. •• van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84 This article reports the Dutch CROSS trial, assessing the efficacy of neoadjuvant chemoradiotherapy (carboplatin/paclitaxel, 41.4Gy) followed by surgery vs surgery alone for locally advanced oesophageal cancer. Although fewer older patients were included, it represents a worldwide standard-of-care for trimodality therapy in oesophageal cancer. Thus, it remains highly relevant in any treatment plan for locally advanced disease.

    PubMed  Google Scholar 

  4. • Stahl M, Budach W. Definitive chemoradiotherapy. J Thorac Dis. 2017;9(Suppl 8):S792–S8 This review discusses the various regimens (both chemotherapy and radiotherapy) used for radical treatment of oesophageal cancer. There is less focus on age however side effect data and long-term remission rate with chemoradiotherapy +/- surgery—which may be a very important factor in the older population.

    PubMed  PubMed Central  Google Scholar 

  5. Shao MS, Wong AT, Schwartz D, Weiner JP, Schreiber D. Definitive or preoperative chemoradiation therapy for esophageal cancer: patterns of care and survival outcomes. Ann Thorac Surg. 2016;101(6):2148–54.

    PubMed  Google Scholar 

  6. Lester SC, Lin SH, Chuong M, Bhooshan N, Liao Z, Arnett AL, et al. A multi-institutional analysis of trimodality therapy for esophageal cancer in elderly patients. Int J Radiat Oncol Biol Phys. 2017;98(4):820–8.

    PubMed  Google Scholar 

  7. •• Guttmann DM, Mitra N, Metz JM, Plastaras J, Feng W, Swisher-McClure S. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer. J Geriatr Oncol. 2018;9(1):40–6 This article reports a large observational cohort study of neoadjuvant chemoradiotherapy specifically in an older population. It confirms the efficacy and tolerability of trimodality therapy in the elderly, confirming previous extrapolations from the CROSS study. Thus, it offers clear evidence for this approach in the elderly and is relevant to treatment decisions in this population.

    PubMed  Google Scholar 

  8. Smith GL, Smith BD, Buchholz TA, Liao Z, Jeter M, Swisher SG, et al. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: the SEER-Medicare cohort. Int J Radiat Oncol Biol Phys. 2009;74(2):482–9.

    PubMed  Google Scholar 

  9. Fogh SE, Yu A, Kubicek GJ, Scott W, Mitchell E, Rosato EL, et al. Do elderly patients experience increased perioperative or postoperative morbidity or mortality when given neoadjuvant chemoradiation before esophagectomy? Int J Radiat Oncol Biol Phys. 2011;80(5):1372–6.

    PubMed  Google Scholar 

  10. Ruol A, Portale G, Castoro C, Merigliano S, Cagol M, Cavallin F, et al. Effects of neoadjuvant therapy on perioperative morbidity in elderly patients undergoing esophagectomy for esophageal cancer. Ann Surg Oncol. 2007;14(11):3243–50.

    PubMed  Google Scholar 

  11. Camerlo A, D'Journo XB, Ouattara M, Trousse D, Doddoli C, Thomas PA. Adenocarcinoma of the esophagus and esophagogastric junction in patients older than 70 years: results of neoadjuvant radiochemotherapy followed by transthoracic esophagectomy. J Visc Surg. 2012;149(3):e203–10.

    CAS  PubMed  Google Scholar 

  12. Bernardi D, Asti E, Aiolfi A, Bonitta G, Luporini A, Bonavina L. Outcome of trimodal therapy in elderly patients with esophageal cancer: prognostic value of the Charlson Comorbidity Index. Anticancer Res. 2018;38(3):1815–20.

    PubMed  Google Scholar 

  13. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128–37.

    PubMed  Google Scholar 

  14. Jougon JB, Ballester M, Duffy J, Dubrez J, Delaisement C, Velly JF, et al. Esophagectomy for cancer in the patient aged 70 years and older. Ann Thorac Surg. 1997;63(5):1423–7.

    CAS  PubMed  Google Scholar 

  15. Honore C, Al-Azzeh A, Gilson N, Van Daele D, Polus M, Meurisse M, et al. Esophageal cancer surgery in patients older than 75: long term results. Acta Chir Belg. 2011;111(1):12–7.

    PubMed  Google Scholar 

  16. Ra J, Paulson EC, Kucharczuk J, Armstrong K, Wirtalla C, Rapaport-Kelz R, et al. Postoperative mortality after esophagectomy for cancer: development of a preoperative risk prediction model. Ann Surg Oncol. 2008;15(6):1577–84.

    PubMed  Google Scholar 

  17. Moskovitz AH, Rizk NP, Venkatraman E, Bains MS, Flores RM, Park BJ, et al. Mortality increases for octogenarians undergoing esophagogastrectomy for esophageal cancer. Ann Thorac Surg. 2006;82(6):2031–6 discussion 6.

    PubMed  Google Scholar 

  18. Adam DJ, Craig SR, Sang CT, Cameron EW, Walker WS. Esophagectomy for carcinoma in the octogenarian. Ann Thorac Surg. 1996;61(1):190–4.

    CAS  PubMed  Google Scholar 

  19. Bonavina L, Incarbone R, Saino G, Clesi P, Peracchia A. Clinical outcome and survival after esophagectomy for carcinoma in elderly patients. Dis Esophagus. 2003;16(2):90–3.

    CAS  PubMed  Google Scholar 

  20. Rice DC, Correa AM, Vaporciyan AA, Sodhi N, Smythe WR, Swisher SG, et al. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg. 2005;79(2):391–7 discussion −7.

    PubMed  Google Scholar 

  21. Morita M, Egashira A, Yoshida R, Ikeda K, Ohgaki K, Shibahara K, et al. Esophagectomy in patients 80 years of age and older with carcinoma of the thoracic esophagus. J Gastroenterol. 2008;43(5):345–51.

    PubMed  Google Scholar 

  22. Pultrum BB, Bosch DJ, Nijsten MW, Rodgers MG, Groen H, Slaets JP, et al. Extended esophagectomy in elderly patients with esophageal cancer: minor effect of age alone in determining the postoperative course and survival. Ann Surg Oncol. 2010;17(6):1572–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Cijs TM, Verhoef C, Steyerberg EW, Koppert LB, Tran TC, Wijnhoven BP, et al. Outcome of esophagectomy for cancer in elderly patients. Ann Thorac Surg. 2010;90(3):900–7.

    PubMed  Google Scholar 

  24. Finlayson E, Fan Z, Birkmeyer JD. Outcomes in octogenarians undergoing high-risk cancer operation: a national study. J Am Coll Surg. 2007;205(6):729–34.

    PubMed  Google Scholar 

  25. Zhang X, Yang Y, Ye B, Sun Y, Guo X, Hua R, et al. Minimally invasive esophagectomy is a safe surgical treatment for locally advanced pathologic T3 esophageal squamous cell carcinoma. J Thorac Dis. 2017;9(9):2982–91.

    PubMed  PubMed Central  Google Scholar 

  26. Biere SS, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;379(9829):1887–92.

    PubMed  Google Scholar 

  27. Nagpal K, Ahmed K, Vats A, Yakoub D, James D, Ashrafian H, et al. Is minimally invasive surgery beneficial in the management of esophageal cancer? A meta-analysis. Surg Endosc. 2010;24(7):1621–9.

    PubMed  Google Scholar 

  28. Dantoc M, Cox MR, Eslick GD. Evidence to support the use of minimally invasive esophagectomy for esophageal cancer: a meta-analysis. Arch Surg. 2012;147(8):768–76.

    PubMed  Google Scholar 

  29. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593–8.

    CAS  PubMed  Google Scholar 

  30. Honing J, Smit JK, Muijs CT, Burgerhof JG, de Groot JW, Paardekooper G, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol. 2014;25(3):638–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Tougeron D, Di Fiore F, Thureau S, Berbera N, Iwanicki-Caron I, Hamidou H, et al. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer. 2008;99(10):1586–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Anderson SE, Minsky BD, Bains M, Hummer A, Kelsen D, Ilson DH. Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer. 2007;96(12):1823–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Tougeron D, Hamidou H, Scotte M, Di Fiore F, Antonietti M, Paillot B, et al. Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes. BMC Cancer. 2010;10:510.

    PubMed  PubMed Central  Google Scholar 

  34. Munch S, Heinrich C, Habermehl D, Oechsner M, Combs SE, Duma MN. Primary radio(chemo)therapy for esophageal cancer in elderly patients: are efficiency and toxicity comparable with younger patients? Eur J Med Res. 2017;22(1):24.

    PubMed  PubMed Central  Google Scholar 

  35. Lu X, Wu H, Wang J, Xu J. Short- and long-term outcomes of definitive chemoradiotherapy in patients with esophageal carcinoma aged >/=75 years. Mol Clin Oncol. 2014;2(2):297–301.

    PubMed  Google Scholar 

  36. Xu C, Xi M, Moreno A, Shiraishi Y, Hobbs BP, Huang M, et al. Definitive chemoradiation therapy for esophageal cancer in the elderly: clinical outcomes for patients exceeding 80 years old. Int J Radiat Oncol Biol Phys. 2017;98(4):811–9.

    PubMed  Google Scholar 

  37. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2310–7.

    PubMed  Google Scholar 

  38. Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–8.

    CAS  PubMed  Google Scholar 

  39. Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, et al. CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. J Clin Oncol. 2016;34(23):2736–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28(9):1547–53.

    CAS  PubMed  Google Scholar 

  41. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435–42.

    CAS  PubMed  Google Scholar 

  42. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20(8):1996–2004.

    CAS  PubMed  Google Scholar 

  43. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15(1):261–7.

    CAS  PubMed  Google Scholar 

  44. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903–9.

    CAS  PubMed  Google Scholar 

  45. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46.

    CAS  PubMed  Google Scholar 

  46. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33(8):1216–20.

    CAS  PubMed  Google Scholar 

  47. Kok TC, van der Gaast A, Splinter TA. 5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group. Ann Oncol. 1996;7(5):533–4.

    CAS  PubMed  Google Scholar 

  48. Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol. 2007;18(5):898–902.

    CAS  PubMed  Google Scholar 

  49. Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15(6):955–9.

    CAS  PubMed  Google Scholar 

  50. Jatoi A, Foster NR, Egner JR, Burch PA, Stella PJ, Rubin J, et al. Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. Int J Oncol. 2010;36(3):601–6.

    CAS  PubMed  Google Scholar 

  51. Berger AK, Zschaebitz S, Komander C, Jager D, Haag GM. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: a retrospective cohort study at the National Center for Tumor Diseases, Heidelberg. World J Gastroenterol. 2015;21(16):4911–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24(31):4991–7.

    PubMed  Google Scholar 

  53. Al-Batran SE, Pauligk C, Homann N, Hartmann JT, Moehler M, Probst S, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur J Cancer. 2013;49(4):835–42.

    PubMed  Google Scholar 

  54. Hofheinz RD, Al-Batran SE, Ridwelski K, Gorg C, Wehle K, Birth M, et al. Population-based patterns of care in the first-line treatment of patients with advanced esophagogastric adenocarcinoma in Germany. Onkologie. 2010;33(10):512–8.

    PubMed  Google Scholar 

  55. Morris H. Dysphagia in the elderly - a management challenge for nurses. Br J Nurs. 2006;15(10):558–62.

    PubMed  Google Scholar 

  56. Bloem BR, Lagaay AM, van Beek W, Haan J, Roos RA, Wintzen AR. Prevalence of subjective dysphagia in community residents aged over 87. BMJ. 1990;300(6726):721–2.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Diamantis G, Scarpa M, Bocus P, Realdon S, Castoro C, Ancona E, et al. Quality of life in patients with esophageal stenting for the palliation of malignant dysphagia. World J Gastroenterol: WJG. 2011;17(2):144–50.

    PubMed  PubMed Central  Google Scholar 

  58. Amdal CD, Jacobsen AB, Guren MG, Bjordal K. Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review. Acta Oncol. 2013;52(4):679–90.

    CAS  PubMed  Google Scholar 

  59. Kassam Z, Wong RK, Ringash J, Ung Y, Kamra J, DeBoer G, et al. A phase I/II study to evaluate the toxicity and efficacy of accelerated fractionation radiotherapy for the palliation of dysphagia from carcinoma of the oesophagus. Clin Oncol (R Coll Radiol). 2008;20(1):53–60.

    CAS  Google Scholar 

  60. Hayter CR, Huff-Winters C, Paszat L, Youssef YM, Shelley WE, Schulze K. A prospective trial of short-course radiotherapy plus chemotherapy for palliation of dysphagia from advanced esophageal cancer. Radiother Oncol. 2000;56(3):329–33.

    CAS  PubMed  Google Scholar 

  61. Fuccio L, Mandolesi D, Farioli A, Hassan C, Frazzoni L, Guido A, et al. Brachytherapy for the palliation of dysphagia owing to esophageal cancer: a systematic review and meta-analysis of prospective studies. Radiother Oncol. 2017;122(3):332–9.

    PubMed  Google Scholar 

  62. Singh P, Singh A, Singh A, Sharma G, Bhatia PK, Grover AS. Long term outcome in patients with esophageal stenting for cancer esophagus - our experience at a Rural Hospital of Punjab, India. J Clin Diagn Res. 2016;10(12):PC06–PC9.

    PubMed  PubMed Central  Google Scholar 

  63. Kim KY, Tsauo J, Song H-Y, Kim PH, Park J-H. Self-expandable metallic stent placement for the palliation of esophageal cancer. J Korean Med Sci. 2017;32(7):1062–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Sharma P, Kozarek R. Role of esophageal stents in benign and malignant diseases. Am J Gastroenterol. 2010;105(2):258–73 quiz 74.

    PubMed  Google Scholar 

  65. Mocanu A. Endoscopic palliation of advanced esophageal cancer. J Med Life. 2015;8:193–201.

  66. Yoon HY, Cheon YK, Choi HJ, Shim CS. Role of photodynamic therapy in the palliation of obstructing esophageal cancer. Korean J Intern Med. 2012;27(3):278–84.

    PubMed  PubMed Central  Google Scholar 

  67. Luketich JD, Christie NA, Buenaventura PO, Weigel TL, Keenan RJ, Nguyen NT. Endoscopic photodynamic therapy for obstructing esophageal cancer: 77 cases over a 2-year period. Surg Endosc. 2000;14(7):653–7.

    CAS  PubMed  Google Scholar 

  68. Ye X-J, Ji Y-B, Ma B-W, Huang D-D, Chen W-Z, Pan Z-Y, et al. Comparison of three common nutritional screening tools with the new European Society for Clinical Nutrition and Metabolism (ESPEN) criteria for malnutrition among patients with geriatric gastrointestinal cancer: a prospective study in China. BMJ Open. 2018;8(4):e019750.

    PubMed  PubMed Central  Google Scholar 

  69. • Pressoir M, Desné S, Berchery D, Rossignol G, Poiree B, Meslier M, et al. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer. 2010;102:966 This article reports the incidence of malnutrition in an undifferentiated French oncology population. It is relevant both to the underlying incidence of malnutrition and to its impact on survival.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. • Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. J Diabetes Metab Disord. 2017;16:21 This article reports overall sarcopaenia rates worldwide in the older population—which continue to rise with advancing age. This is of particular relevance to oesophageal cancer given the significantly increased complications (especially surgical complications) associated with sarcopaenia.

    PubMed  PubMed Central  Google Scholar 

  71. Makary MA, Segev DL, Pronovost PJ, Syin D, Bandeen-Roche K, Patel P, et al. Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg. 2010;210(6):901–8.

    PubMed  Google Scholar 

  72. Sundermann S, Dademasch A, Praetorius J, Kempfert J, Dewey T, Falk V, et al. Comprehensive assessment of frailty for elderly high-risk patients undergoing cardiac surgery. Eur J Cardiothorac Surg. 2011;39(1):33–7.

    PubMed  Google Scholar 

  73. Afilalo J, Eisenberg MJ, Morin JF, Bergman H, Monette J, Noiseux N, et al. Gait speed as an incremental predictor of mortality and major morbidity in elderly patients undergoing cardiac surgery. J Am Coll Cardiol. 2010;56(20):1668–76.

    PubMed  Google Scholar 

  74. Rostoft S, Audisio RA. Recent advances in cancer surgery in older patients. F1000Research. 2017;6:1242.

    PubMed  PubMed Central  Google Scholar 

  75. Gill TM, Gahbauer EA, Allore HG, Han L. Transitions between frailty states among community-living older persons. Arch Intern Med. 2006;166(4):418–23.

    PubMed  Google Scholar 

  76. Forster A, Lambley R, Young JB. Is physical rehabilitation for older people in long-term care effective? Findings from a systematic review. Age Ageing. 2010;39(2):169–75.

    PubMed  Google Scholar 

  77. Partridge JS, Harari D, Martin FC, Dhesi JK. The impact of pre-operative comprehensive geriatric assessment on postoperative outcomes in older patients undergoing scheduled surgery: a systematic review. Anaesthesia. 2014;69(Suppl 1):8–16.

    PubMed  Google Scholar 

  78. Partridge J, Sbai M, Dhesi J. Proactive care of older people undergoing surgery. Aging Clin Exp Res. 2018;30(3):253–7.

    PubMed  PubMed Central  Google Scholar 

  79. Partridge JS, Harari D, Martin FC, Peacock JL, Bell R, Mohammed A, et al. Randomized clinical trial of comprehensive geriatric assessment and optimization in vascular surgery. Br J Surg. 2017;104(6):679–87.

    CAS  PubMed  Google Scholar 

  80. McIsaac DI, Huang A, Wong CA, Wijeysundera DN, Bryson GL, van Walraven C. Effect of preoperative geriatric evaluation on outcomes after elective surgery: a population-based study. J Am Geriatr Soc. 2017;65(12):2665–72.

    PubMed  Google Scholar 

  81. Le Roy B, Pereira B, Bouteloup C, Costes F, Richard R, Selvy M, et al. Effect of prehabilitation in gastro-oesophageal adenocarcinoma: study protocol of a multicentric, randomised, control trial-the PREHAB study. BMJ Open. 2016;6(12):e012876.

    PubMed  PubMed Central  Google Scholar 

  82. Harari D, Hopper A, Dhesi J, Babic-Illman G, Lockwood L, Martin F. Proactive care of older people undergoing surgery ('POPS'): designing, embedding, evaluating and funding a comprehensive geriatric assessment service for older elective surgical patients. Age Ageing. 2007;36(2):190–6.

    PubMed  Google Scholar 

  83. Mohile SG, Xian Y, Dale W, Fisher SG, Rodin M, Morrow GR, et al. Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries. J Natl Cancer Inst. 2009;101(17):1206–15.

    PubMed  PubMed Central  Google Scholar 

  84. Guerard EJ, Deal AM, Williams GR, Jolly TA, Nyrop KA, Muss HB. Falls in older adults with cancer: evaluation by oncology providers. J Oncol Pract. 2015;11(6):470–4.

    PubMed  PubMed Central  Google Scholar 

  85. Jolly TA, Deal AM, Nyrop KA, Williams GR, Pergolotti M, Wood WA, et al. Geriatric assessment-identified deficits in older cancer patients with normal performance status. Oncologist. 2015;20(4):379–85.

    PubMed  PubMed Central  Google Scholar 

  86. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–603.

    PubMed  PubMed Central  Google Scholar 

  87. Puts MT, Santos B, Hardt J, Monette J, Girre V, Atenafu EG, et al. An update on a systematic review of the use of geriatric assessment for older adults in oncology. Ann Oncol. 2014;25(2):307–15.

    CAS  PubMed  Google Scholar 

  88. Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377–86.

    PubMed  Google Scholar 

  89. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Department, University Hospital Waterford, Dunmore Road, Waterford, X91 ER8E, Ireland

    Dara Bracken-Clarke, Abdul Rehman Farooq & Anne M. Horgan

Authors
  1. Dara Bracken-Clarke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abdul Rehman Farooq
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne M. Horgan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne M. Horgan.

Ethics declarations

Conflict of Interest

Dara Bracken-Clarke, Abdul Rehman Farooq, and Anne M. Horgan declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Geriatric Oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bracken-Clarke, D., Farooq, A.R. & Horgan, A.M. Management of Locally Advanced and Metastatic Esophageal Cancer in the Older Population. Curr Oncol Rep 20, 99 (2018). https://doi.org/10.1007/s11912-018-0745-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-018-0745-3

Keywords

Search

Navigation